“Mipomersen sodium did not exhibit genotoxic potential in a battery of studies, including the in vitro Bacterial Reverse Mutation (Ames) assay, an in vitro cytogenetics assay using a mouse lymphoma cell line, and an in vivo micronucleus assay in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
“The Committee concluded that hepatocellular adenomas and combined hepatocellular adenomas or carcinomas were drug-related in female mice administered 60 mg/kg/week mipomersen.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Mouse fertility/EFD and rabbit EFD (not teratogenic); rat PPND pup effects; juvenile rat study
“Mipomersen was not teratogenic in mice or rabbits at doses providing modest margins of exposure (2 to 5 times) compared to humans.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Safety pharmacology
hERG, mouse respiratory and Irwin studies; CV telemetry within 13-week monkey tox study
“Heart rate, mean arterial pressure and EKG were evaluated by telemetry in monkeys after single and repeat doses of 3 to 35 mg/kg/wk for 13 weeks (Study AS02).”
✓ VerifiedFDA pharmacology/toxicology review, p. 39Source ↗
Genotox: Ames
Negative
“Mipomersen sodium did not exhibit genotoxic potential in a battery of studies, including the in vitro Bacterial Reverse Mutation (Ames) assay, an in vitro cytogenetics assay using a mouse lymphoma cell line, and an in vivo micronucleus assay in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Genotox: in vitro mammalian
Mouse lymphoma cytogenetics assay: negative
“Mipomersen sodium did not exhibit genotoxic potential in a battery of studies, including the in vitro Bacterial Reverse Mutation (Ames) assay, an in vitro cytogenetics assay using a mouse lymphoma cell line, and an in vivo micronucleus assay in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Genotox: in vivo
Mouse micronucleus: negative
“Mipomersen sodium did not exhibit genotoxic potential in a battery of studies, including the in vitro Bacterial Reverse Mutation (Ames) assay, an in vitro cytogenetics assay using a mouse lymphoma cell line, and an in vivo micronucleus assay in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Carcinogenicity model
2-year mouse and rat (mipomersen plus species-specific surrogate)
“2-year carcinogenicity studies were conducted in both the mouse and the rat with mipomersen and the relevant species-specific surrogate.”
✓ VerifiedFDA pharmacology/toxicology review, p. 26Source ↗
Carcinogenicity timing
2-year rat and mouse studies completed before the marketing application and found adequate by ECAC
“Two year carcinogenicity studies of mipomersen were conducted in rats and mice. The Executive Carcinogenicity Assessment Committee found the studies adequate.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
hERG / QT
Negative in hERG assay
“Conclusion was mipomersen was negative in hERG assay.”
✓ VerifiedFDA pharmacology/toxicology review, p. 39Source ↗